TY - JOUR
T1 - The effect of triphasic oral contraceptives on plasma lipids and lipoproteins
AU - Patsch, Wolfgang
AU - Brown, Spencer A.
AU - Gotto, Antonio
AU - Young, Ronald L.
PY - 1989/1/1
Y1 - 1989/1/1
N2 - To determine the effect of triphasic oral contraceptives on plasma lipid transport, 150 nonsmoking women with normolipidemia, ages 18 to 35 years, were randomly assigned to receive one of three contraceptive formulations: (1) ethinyl estradiol, 30, 40, and 30 μg/day, each for 6, 5, and 10 days per menstrual cycle, and levonorgestrel, 50, 75, and 125 μg/day, each for 6, 5, and 10 days; (2) ethinyl estradiol, 35 μg/day for 21 days, and phased norethindrone, 500, 750, and 1000 μg/day each for 7 consecutive days; and (3) ethinyl estradiol, 35 μg/day for 21 consecutive days, and norethindrone, 500, 1000, and 500 μg/day for 7, 9, and 5 days, respectively. A control group consisting of 49 women taking a nonhormonal form of contraception was also included. After 6 months of oral contraceptive treatment, significant increases in plasma triglyceride (28% to 52%) and plasma apolipoprotein B levels (20% to 23%) were observed in each treatment group. The changes in total plasma cholesterol (3% to 10%) and low-density lipoprotein cholesterol values (0% to 11%) were less striking. Changes in total high-density lipoprotein cholesterol levels were statistically insignificant (-2% to -4%); however, high-density lipoprotein2 cholesterol levels decreased by 29% to 33% and high-density lipoprotein3 cholesterol levels increased by 20% to 23%. Concomitantly, plasma apolipoprotein A-I values increased by 5% to 12%. No consistent significant differences among analyses, were observed between any of the groups receiving different oral contraceptives for 6 months.
AB - To determine the effect of triphasic oral contraceptives on plasma lipid transport, 150 nonsmoking women with normolipidemia, ages 18 to 35 years, were randomly assigned to receive one of three contraceptive formulations: (1) ethinyl estradiol, 30, 40, and 30 μg/day, each for 6, 5, and 10 days per menstrual cycle, and levonorgestrel, 50, 75, and 125 μg/day, each for 6, 5, and 10 days; (2) ethinyl estradiol, 35 μg/day for 21 days, and phased norethindrone, 500, 750, and 1000 μg/day each for 7 consecutive days; and (3) ethinyl estradiol, 35 μg/day for 21 consecutive days, and norethindrone, 500, 1000, and 500 μg/day for 7, 9, and 5 days, respectively. A control group consisting of 49 women taking a nonhormonal form of contraception was also included. After 6 months of oral contraceptive treatment, significant increases in plasma triglyceride (28% to 52%) and plasma apolipoprotein B levels (20% to 23%) were observed in each treatment group. The changes in total plasma cholesterol (3% to 10%) and low-density lipoprotein cholesterol values (0% to 11%) were less striking. Changes in total high-density lipoprotein cholesterol levels were statistically insignificant (-2% to -4%); however, high-density lipoprotein2 cholesterol levels decreased by 29% to 33% and high-density lipoprotein3 cholesterol levels increased by 20% to 23%. Concomitantly, plasma apolipoprotein A-I values increased by 5% to 12%. No consistent significant differences among analyses, were observed between any of the groups receiving different oral contraceptives for 6 months.
KW - cholesterol
KW - comparative trial
KW - lipids
KW - Oral contraceptives
UR - http://www.scopus.com/inward/record.url?scp=0024398192&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024398192&partnerID=8YFLogxK
U2 - 10.1016/0002-9378(89)90703-5
DO - 10.1016/0002-9378(89)90703-5
M3 - Article
C2 - 2686455
AN - SCOPUS:0024398192
SN - 0002-9378
VL - 161
SP - 1396
EP - 1401
JO - American Journal of Obstetrics and Gynecology
JF - American Journal of Obstetrics and Gynecology
IS - 5
ER -